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Protocol
AbstrACt
Introduction Hyperglycaemia is common in the 
very preterm infant and has been associated with 
adverse outcomes. Preventing hyperglycaemia without 
increasing the risk of hypoglycaemia has proved 
challenging. The development of real-time continuous 
glucose monitors (CGM) to inform treatment decisions 
provides an opportunity to reduce this risk. This study 
aims to assess the feasibility of CGM combined with a 
specifically designed paper guideline to target glucose 
control in the preterm infant.
Methods and analyses The Real Time Continuous 
Glucose Monitoring in Neonatal Intensive Care (REACT) 
trial is an international multicentre randomised 
controlled trial. 200 preterm infants ≤1200 g and 
≤24 hours of age will be randomly allocated to either 
real-time CGM or standard care (with blinded CGM data 
collection). The primary outcome is time in target 2.6–
10 mmol/L during the study intervention assessed using 
CGM. Secondary outcomes include efficacy relating 
to glucose control, utility including staff acceptability, 
safety outcomes relating to incidence and prevalence of 
hypoglycaemia and health economic analyses.
Ethics and dissemination The REACT trial has been 
approved by the National Health Service Health Research 
Authority National Research Ethics Service Committee 
East of England (Cambridge Central); Medical Ethics 
Review Committee, VU University Medical Centre, 
Amsterdam, The Netherlands and the Research Ethics 
Committee, Sant Joan de Déu Research Foundation, 
Barcelona, Spain. Recruitment began in July 2016 and will 
continue until mid-2018. The trial has been adopted by 
the National Institute of Health Research Clinical Research 
Network portfolio (ID: 18826) and is registered with 
anInternational Standard Randomised Control Number 
(ISRCTN registry ID: 12793535). Dissemination plans 
include presentations at scientific conferences, scientific 
publications and efforts at stakeholder engagement.
trial registration number ISRCTN12793535; Pre-results.
IntroduCtIon 
In utero, glucose levels are normally main-
tained between 4 and 6 mmol/L,1 but infants 
born preterm are at risk of both hypergly-
caemia and hypoglycaemia.2 Hyperglycaemia 
and hypoglycaemia have both been associ-
ated with increased mortality and morbidity 
of preterm babies.3 4 Hyperglycaemia can 
lead to acute problems of a persistent osmotic 
diuresis and metabolic acidosis which can 
be difficult to control and has been associ-
ated with increased risk of intraventricular 
haemorrhage and patent ductus arteriosus.5 
Hyperglycaemia has also been associated with 
increased long-term morbidity, including 
increased risk of retinopathy of prematu-
rity.4 6–8 Hypoglycaemia is associated with 
characteristic occipital temporal lesions.8 
Attempts to reduce risks associated with 
hyperglycaemia in adult and paediatric and 
neonatal intensive care (NICU) have resulted 
in increased risk of hypoglycaemia.9–11 This is 
strengths and limitations of this study
 ► The comparison of real-time continuous glucose 
monitoring (CGM) data with blinded CGM data in the 
control study arm will provide detailed comparable 
data on efficacy and safety between study arms.
 ► As an international multicentre trial, the results will 
be generalisable across a range of neonatal inten-
sive care settings.
 ► Input by staff and parents within the trial itself as 
well as part of the trial management will provide in-
formation on utility and facilitate translation of the 
outcomes into clinical practice.
 ► The study requires recruitment within 24 hours of 
preterm birth which requires a significant commit-
ment from the clinical and research teams if it is to 
be successful.
 ► The study is powered to detect a difference in the 
primary outcome ‘time in target’ (2.6–10 mmol/L), 
but will not have the power to detect the impact on 
clinical outcomes.
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of particular concern for the very preterm infant in whom 
there is very varied insulin sensitivity, which increases the 
risk of hypoglycaemia. In addition the developing brain 
appears to be particularly vulnerable to both hyper-
glycaemic12 and hypoglycaemic insults. Early postnatal 
glucose control may be an important modifiable risk 
factor for clinical outcomes. A recent Cochrane review 
has highlighted the need for further studies into the 
impact of interventions to improve glucose control in 
these infants.13 
Managing glucose control is dependent in part on 
methods of measuring and monitoring glucose levels. 
Within NICU glucose measurements are currently limited 
to intermittent blood sampling,14 with long periods when 
glucose levels are unknown. In contrast, other physiolog-
ical parameters such as oxygen saturation, blood pressure 
and heart rate are all monitored continuously to prevent 
wide fluctuations. It is increasingly thought that fluctua-
tions in glucose levels may also have a significant impact 
on long-term outcomes.15 The reason for the intermittent 
measurement is that current methodologies rely on blood 
sampling either from a central arterial line or by heel 
prick. Clinical care for preterm infants aims to reduce the 
frequency of handling16 and volume of blood sampled as 
this has been shown to improve outcomes.
Developments in the measurement of glucose levels 
in patients with diabetes mellitus include continuous 
glucose monitoring (CGM) of interstitial glucose 
levels.17 Real-time data on interstitial glucose levels now 
provides information on glucose trends with the poten-
tial for earlier intervention and prevention of both 
hyperglycaemia and hypoglycaemia. Benefits within 
adult intensive care remain controversial,18 however, the 
benefits in the setting of NICU may be more marked as 
blood glucose (BG) measurements are taken much less 
frequently in these small babies. There have also been 
key developments in the technology including extended 
life of sensors (previously 72 hours) and improved 
accuracy.19 The latter is particularly relevant due to the 
threshold levels of hypoglycaemia and hyperglycaemia 
(<2.6 and >10 mmol/L) which are more extreme than in 
adults and are at the limits of accuracy of many methods 
of glucose measurement.
Blinded CGM has been used in preterm babies within 
clinical trials,2 20 21 and studies of real-time devices 
have shown a benefit in providing early warning of 
and prevention of hypoglycaemia.22 Studies have not 
so far attempted to use CGM to guide clinical manage-
ment to support the targeting of glucose control in 
preterm infants. A single-centre feasibility study of the 
real-time monitors demonstrated that sensor glucose 
(SG) values are comparable with BG values (Real Time 
Continuous Glucose Monitoring in Neonatal Intensive 
Care (REACT) feasibility study REC Ref: 14/EE/0127). 
Data from the feasibility study have helped to design 
this randomised controlled trial. This multicentre 
randomised controlled trial will determine whether 
real-time CGM, with support from a paper algorithm, 
can help improve the management of glucose control 
in terms of efficacy, safety and clinical acceptability. 
This will not only enhance the short-term management 
of glucose control in infants requiring intensive care 
but by reducing the risks associated with both hyper-
glycaemia and hypoglycaemia may impact on long-term 
clinical outcomes.
trIAl objECtIvEs
The REACT trial will evaluate efficacy, safety, utility and 
cost-effectiveness of real-time CGM in preterm infants 
in NICU. Our primary hypothesis is that the use of 
real-time CGM will improve the time a baby’s glucose 
levels (measured using CGM) remain within the target 
2.6–10 mmol/L (widely accepted clinical target for 
glucose control), compared with standard clinical prac-
tice (with blinded CGM data collection). Secondary 
objectives include evaluation of clinical acceptability 
in the preterm infant (using staff and parent question-
naires) and safety in relation to the device itself and risk 
of hypoglycaemia.
MEthods
study design
This is a multicentre interventional, randomised 
controlled trial of CGM compared with standard clinical 
management (control). We will recruit potential partic-
ipants within 24 hours of birth and continually monitor 
their glucose levels for 6 days. Data will be collected until 
36 weeks corrected gestational age. No other aspects of 
concomitant care are prohibited during the trial.
Eligibility criteria
Inclusion criteria
Infants who have a birth weight ≤1200 g, are ≤24 hours of 
age, ≤33+6 weeks gestation and in whom written informed 
parental consent has been received.
Exclusion criteria
Any lethal congenital abnormality known at trial entry, 
any congenital metabolic disorder known at trial entry 
and any neonates who, in the opinion of the treating clini-
cian at trial entry, have no realistic prospect of survival.
Intervention
Babies will be randomised in a 1:1 ratio, into control 
and intervention arms of the study using a web rando-
misation system, Trans European Network ALEA software 
(TENALEA). This is an open study in which the clinical 
staff, research team and parents will be aware of the study 
arm and intervention. All babies will have a subcutaneous 
sensor inserted, Enlite (Medtronic) that will be linked to 
a Medtronic MiniMed 640G system and will be calibrated 
with point of care BG levels. For consistency across sites 
calibration will be standardised by providing all units with 
Nova StatStrip meters.
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Standard care with blinded CGM data collection (control)
These infants will have their glucose control monitored 
and managed according to standard clinical practice 
using intermittently sampled BG levels. Nutritional 
delivery (including glucose) and insulin delivery will be 
prescribed according to the standard clinical guidelines 
within each unit. The CGM device will collect glucose 
data continuously, but the clinical team will be blinded to 
the data as the monitor will be kept covered and fastened 
with a tamper proof seal.
Real-time CGM device with paper algorithm (intervention)
The CGM data will be open to view by the clinical team 
during the first week of the baby’s life and the staff will 
be advised to read and record the SG data hourly as part 
of standard clinical monitoring. This will support staff 
to use the additional data available from real-time moni-
toring to guide timing of BG measurement and changes 
in clinical management. Interventions to target glucose 
control will then be guided by the specifically designed 
paper algorithm (Supplementary file). This algorithm 
was developed during the REACT feasibility study (REC 
Ref: 14/EE/0127).
Medical devices: MiniMed 640G system
The MiniMed 640G system is indicated for glucose 
monitoring and for continuous delivery of insulin, 
for the management of diabetes mellitus in persons 
requiring insulin. Monitoring equipment only will be 
used for this study. The system being used comprises 
linking the Enlite sensor (Medtronic, Northridge, Cali-
fornia, USA) using the Guardian 2 Link transmitter to 
the MiniMed 640G which then displays the glucose data 
in real time.
Sensor
The Enlite sensor (Medtronic) is a CGM sensor which 
received CE mark in 2013 (CE certificate No. 21024). 
The sensor (figure 1) comprises a disposable subcuta-
neous oxidase-based platinum electrode that catalyses 
interstitial glucose generating an electrical current 
every 10 s which is transmitted to a monitor for display 
and/or recording. The data will be recorded and/or 
displayed as an averaged value every 5 min, giving a 
total of 288 readings per day. Glucose values outside the 
range 2.2–24.0 mmol/L (40–430 mg/dL) are reported 
as <2.2 mmol/L (40 mg/dL) or >24 mmol/L (430 mg/
dL), respectively.
The sensor will be inserted subcutaneously (into the 
thigh) by hand, not using the standard insertion device, 
thus ensuring the sensor is inserted into the subcuta-
neous tissue. The sensors are soft and flexible, approx-
imately 8.75 mm in length and are mounted inside a 
hollow needle to allow for subcutaneous insertion. Once 
the sensor is inserted the introducer needle will be with-
drawn, and the sensor attached to a small Guardian 2 
Link transmitter (CE Mark 2013; Certificate No. 8858) 
for data transfer to the MiniMed 640G system for data 
viewing. The sensor will then be secured with a clear 
occlusive dressing (again trimmed to ensure minimal 
contact with the infant’s skin), so that the insertion site 
can be inspected daily. A blood sample will be required 
in every 12 hours to ensure calibration of the sensor. 
Sensors will be removed after 7 days.
Guardian 2 Link transmitter
It connects to the glucose sensor and sends glucose data 
wirelessly to the MiniMed640G device (figure 2).
The MiniMed 640G device
The 640G device as well as providing continuous glucose 
values will store data so that it can be analysed to track 
patterns and improve glucose management. Glucose data 
will be downloaded from the 640G at the end of the study 
Figure 1 The Enlite glucose sensor (Medtronic, Watford 
UK).
Figure 2 The Enlite glucose sensor with The Guardian 2 
Link transmitter attached.
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period to a computer for analyses. This device received 
CE mark in 2014 (CE certificate No. 8857) (figure 3).
blIndInG
To ensure that the real-time data are not available to staff 
caring for babies in the control arm of the study the CGM 
will be kept secure in an opaque bag with tamper tag seals. 
The bags will be opened for calibration in every 12 hours, 
and each baby will have a log kept of timings of when the 
tamper tag is broken/resealed.
outCoMEs
The primary outcome is percentage of time SG in target 
range of 2.6–10 mmol/L. This was selected after consul-
tation as it represents internationally, the clinically most 
widely accepted target range for glucose control for this 
population.
Secondary outcomes have been selected to provide 
further evidence around efficacy, acceptability and safety. 
These include for efficacy:
 ► Mean SG.
 ► Percentage of time SG in range of 4–8 mmol/L.
 ► SG variability within individuals as assessed by within 
patient SD.
 ► Percentage of time glucose levels in hyperglycaemic 
range, SG >15 mmol/L.
Acceptability will be assessed by a specifically designed 
staff questionnaire which will be completed anonymously 
on day 3 and 7 by the clinical team caring for the baby as 
well as a parent questionnaire on day 7.
Safety outcomes include both measures of BG and SG 
to address potential differences in methodologies and 
to provide data on prevalence of exposures that may be 
undetected clinically in the control arm of the study:
 ► Incidence of hypoglycaemia defined as any episode of 
BG >2.2 mmol/L and <2.6 mmol/L.
 ► Incidence of hypoglycaemia defined as continuous 
episode of CGM SG <2.6 mmol/L for >1 hour.
 ► Incidence of severe hypoglycaemia defined as any 
episode of BG ≤2.2 mmol/L.
Health economics: cost-effectiveness will be expressed 
in terms of incremental cost per additional case of 
adequate glucose control between 2.6 and 10 mmol/L.
sAMplE sIzE
Based on data from the REACT feasibility study and histor-
ical control data, we conservatively assume that the SD of 
the primary endpoint is 22%. A sample size of 200 partic-
ipants will enable a treatment effect of a 10% increase in 
the mean value of the primary endpoint to be detected 
with 90% power using a two-sided 5% significance test 
in the primary analysis. Based on a consensus of expert 
opinion a difference of 10% is believed to be of minimal 
clinical relevance. It is expected that a small number of 
patients will be withdrawn from the study. Reasons for 
these withdrawals include transfer to participant’s local 
NICU, withdrawal of parental consent or death.
rECruItMEnt plAn
All babies will be recruited within 24 hours of birth 
at one of the NICUs that has been approved for study 
participation. Due to the short  time frame from birth to 
recruitment potentially eligible babies will be identified 
in a number of ways: (1) liaison with the obstetric team to 
highlight mothers at risk of preterm delivery, (2) liaison 
with the neonatal transport team to identify babies who 
have been born in local units being transferred to a study 
centre and (3) liaison with the NICU clinical team of 
study centres. Screening of eligible patients will be under-
taken in collaboration with the clinical team and families 
approached only if considered eligible and the families 
consent to being approached about study involvement. 
Screening logs will be reviewed regularly by the coordi-
nating centre to identify any issues around recruitment.
The REACT recruitment centres are level 3 NICUs. 
They have been selected either because of their previous 
experience of using CGM in the preterm infant, or they 
are centres with a proportionately large number of babies Figure 3 MiniMed 640G (Medtronic, Watford UK).
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which would fulfil the study inclusion criteria and repre-
sent an international range of clinical practice and thus 
provide generalisability of the intervention. The first 
patient was recruited in July 2016, and the end of study is 
planned for November 2018.
rAndoMIsAtIon
Randomisation will take place within 24 hours of delivery 
and babies will be randomised in a 1:1 ratio into control 
and intervention arms of the study using a central web 
randomisation system, TENALEA. The randomisation 
will use blocked stratified randomisation. The stratifica-
tion factors will be to recruiting centres and gestation (<26 
weeks gestation, ≥26 weeks gestation). The programme 
will notify the local research team of treatment alloca-
tion who will then inform their clinical team regarding 
the practicalities of management. This is an open study in 
which the clinical and research teams and parents will be 
aware of the study arm and intervention.
dAtA MAnAGEMEnt And AnAlysEs
Data collection will be undertaken from birth to 36 weeks 
corrected gestational age. If a baby has been discharged 
from their recruiting NICU, the research team will use local 
and national databases, local contacts and links with parents 
to ensure complete follow-up data is obtained. All data will 
be sent to the coordinating centre in Cambridge where it 
will be entered onto a MACRO database. All data will be 
collected, transferred and stored to comply with Good Clin-
ical Practice (GCP) and Data Protection legislation. Access 
to data will only be granted to authorised personnel involved 
in study management or for auditing/monitoring to comply 
with regulations. To maintain high-quality standard of data 
entry, the data base will be tested and validated prior to use.
Efficacy
This will be assessed by comparison of data collected by 
real-time CGM in the intervention arm and blinded CGM 
in the control infants.
Clinical acceptability
Parents, nurses and medical staff, caring for babies in the 
study will be asked to complete study-specific questionnaires.
safety
 This will be assessed in three areas: incidence of hypo-
glycaemia measured as part of clinical care (BG levels) 
and after review of SG data; device safety through adverse 
device effect (ADE) reporting; and acute mortality and 
morbidity outcomes as part of the case report form (CRF).
Costs for economic evaluation
 Data will be collected on the health service resources 
used in the treatment of infants during the period 
between randomisation and 36 weeks gestation and based 
on British Association of Perinatal Medicine standard 
criteria for level of care, as well as neonatal complications. 
Current UK unit costs will be applied to each resource 
item and a per diem cost for each level of neonatal care 
will be based on Department of Health reference costs 
calculated on a full absorption costing basis.
dAtA AnAlysEs
The primary endpoint will be analysed using linear 
regression to estimate the absolute difference in time 
SG in target of 2.6–10 mmol/L, adjusting for baseline 
variables (centre, gestation). Analyses will be under-
taken both for intention to treat and as treated popula-
tions. Estimates of treatment effect, with 95% CIs and 
p values will be provided. Secondary endpoints that are 
continuous variables will be analysed in a similar fashion. 
Secondary endpoints that are counts or binary variables 
will be analysed using an appropriate regression frame-
work. Methods will be used to reduce the likelihood of a 
type I error. All of the efficacy endpoints will be ranked in 
order of importance: mean SG, percentage of time SG in 
target of 4–8 mmol/L, SG variability within individuals as 
assessed by within-patient SD, percentage of time glucose 
levels in hyperglycaemic range—SG >15 mmol/L.
Continuous variables will report the mean, median, SD, 
range, maximum and minimum. Binary or categorical 
endpoints will be represented using frequency tables in 
the ‘p% (r/n)’ format. The analysis will look for a treat-
ment interaction effect with the following baseline vari-
ables: centre, sex, corrected gestational age, birthweight 
SDs, use of antenatal steroids, maternal chorioamnionitis 
and maternal diabetes using the regression framework in 
an exploratory, non-confirmatory manner.
An incremental cost-effectiveness analysis will be 
performed. In the baseline analysis, the economic evalua-
tion will be expressed as the incremental cost per additional 
case of adequate glucose control. Adequate control will be 
considered as 80% of time in target. Given the multina-
tional nature of the trial, the hierarchical structures of the 
cost and outcomes data will be taken into account in the 
analysis plan. Due to the known limitations of within-trial 
economic evaluations, we will also construct a decision-an-
alytical model to model the cost-effectiveness of CGM 
beyond the time horizon of the trial.
sItE trAInInG
Research teams at each site will be required to have up-to-
date GCP training and have undertaken training in study 
procedures including use of the CGM and Nova Biomedical 
point of care devices. Paper and online resources as well as 
a call line will be available to support the research teams.
MonItorInG
Data returns will be continually monitored by the central 
team for completeness and timeliness of all data returned. 
Compliance with intervention strategy in each study arm 
will also be reviewed to ensure there is not ‘crossover’ 
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between study arms. A monitoring plan is in place deter-
mining frequency and scope of site monitoring based 
on continuing risk review. Face-to-face monitoring visits 
will initially be undertaken within the first 6 months and 
then adjusted following assessment of recruitment rate, 
number of data queries and serious adverse event (SAE) 
reports. The study sites will provide direct access to all 
trial-related source data and reports for the purpose of 
monitoring and auditing by the central study team, 
sponsor and regulatory authorities as required.
dAtA And sAfEty MonItorInG
The data and safety monitoring committee (DSMC) 
is responsible for safeguarding the interests of the trial 
participants and making recommendations to the trial 
steering committee (TSC). The REACT DSMC roles and 
responsibilities and operating procedures are defined in 
the REACT DSMC Charter. It is composed of three inde-
pendent multidisciplinary experts who are not involved in 
the conduct of the trial in any way. They met prior to the 
initiation of enrolment and determined a plan to review 
the protocol, compliance, safety and AEs and outcome 
data after a prespecified number of babies have been 
recruited. The TSC is composed of five to six independent 
members and has a Charter defining the member’s roles 
and responsibilities. The TSC provide advice, through its 
chair, to the chief investigator and report to trial sponsor 
and trial funder.
Safety will be assessed continuously during each baby’s 
stay in NICU. The frequency of AE and SAE as defined 
by The International Conference on Harmonisation and 
that would normally require reporting within a clinical 
trial is anticipated to be high in the population being 
studied despite the low risk of the study intervention. 
Following discussions with the Medicines and Healthcare 
Products Regulatory Agency (MHRA) and in accordance 
with regulatory guidance which allows for exceptions in 
such circumstances a modified reporting plan was agreed.
Any ADE will be recorded and reported to the coor-
dinating centre. All device deficiencies that might have 
led to a serious ADE (SADE) if suitable action had not 
been taken; intervention had not been made or if circum-
stances had been less fortunate, will be reported to the 
Sponsor as for SAEs/SADEs. AEs will be recorded in the 
notes and some will be captured as exploratory outcomes 
as part of the CRF. SAEs are common in this population, 
therefore, the MHRA requested the following expecta-
tion for safety reporting:
during the intervention period of the study (study days 1–7)
The following expected SAEs will need to be recorded in 
the CRF (safety log) and reported using the safety report 
form to the sponsor within 24 hours of awareness of the 
event: (1) death, (2) culture positive infection, (3) severe 
hypoglycaemia (<2.6 mmol/L), (4) seizures, (5) any 
other related SAE.
postintervention period (study day 7 until end of study)
Important medical outcomes for the trial will be captured 
in the CRF at the 36 weeks corrected gestation assess-
ment. Other SAEs are anticipated events for this study 
population and do not need to be recorded or reported 
separately as an SAE if judged by the clinical team to be 
unrelated to the study.
EthICs And dIssEMInAtIon
The investigator or a suitably qualified person designated 
by the principal investigator will receive written informed 
consent from the patient’s parent/legally accept-
able representative before any trial-specific activity is 
performed. Clinical trial authorisation has been granted 
by the MHRA (REF: CI/2016/0011). Written approvals 
will be received from individual hospital sites prior to 
recruitment. Approvals have also been obtained from 
Medical Ethics Review Committee, VU University Medical 
Centre, Amsterdam and Heath Care Inspectorate (REF: 
2017–1 398434/VlO 14949), The Netherlands and the 
Research Ethics Committee, Sant Joan de Déu Research 
Foundation, Barcelona, and Ministry of Health Social 
Services and Equality (REF: 591/16/EC), Spain. The 
chief investigator will ensure that the trial is conducted 
in accordance with the principles of the Declaration of 
Helsinki and in conformity with the medical devices regu-
lations and any relevant amendments. The findings of 
the trial will be prepared and presented at national and 
international meetings and conferences and published in 
peer-reviewed journals by the academic team.
pAtIEnt And publIC InvolvEMEnt
Consultation with the parents from the local parent 
support group was undertaken to help inform trial design. 
Parents are being asked to provide feedback on study 
involvement as part of the protocol. The TSC includes a 
lay person. We will send newsletters to parents to update 
them on study progress.
ConClusIons
The REACT trial is an international multicentre trial 
which will randomise 200 preterm babies (≤1200 g 
and ≤24 hours of age) to receive either real-time CGM or 
standard clinical management of glucose control (with 
blinded CGM data collection). This study will determine 
if real-time CGM can support better targeting of glucose 
control in these babies reducing the risk of both hyper-
glycaemia and hypoglycaemia. This has the potential to 
impact on both the acute management, and in the future 
on outcomes of preterm babies who are at risk from 
glucose dysregulation.
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